[Form 4] Idexx Laboratories Inc Insider Trading Activity

Rhea-AI Filing Summary

Martin A. Smith, Executive Vice President of IDEXX Laboratories (IDXX), reported insider transactions dated 09/01/2025. The filing shows an acquisition of 18 shares of IDEXX common stock and a disposition of 5 shares, leaving reported beneficial ownership figures of 1,438.659 and 1,433.659 shares after each transaction respectively. The filing also records 18 restricted stock units (RSUs) tied to those shares; the RSU grant vests in four annual installments beginning September 1, 2022 and represents contingent rights to one share each. The filing discloses that 28.709 shares were purchased earlier under the issuer’s Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. A price of $647.09 is shown for the disposed shares, noted as the Nasdaq closing price on August 29, 2025. The form is signed by an attorney-in-fact on behalf of Mr. Smith.

Positive

• Disclosure of ESPP purchases (28.709 shares) provides transparency on compensation-related acquisitions
• RSU vesting schedule clarity: grant vests in four annual installments beginning September 1, 2022

Negative

• None.

Insights

Financial Analyst

TL;DR: Small-scale insider activity with negligible immediate financial impact on IDXX.

The transactions reported are small in absolute share count: an 18-share acquisition and a 5-share disposition, leaving beneficial ownership around ~1,434 shares. Such volumes are immaterial relative to a large-cap issuer and do not meaningfully change ownership concentration or capital structure. The notation that 28.709 shares were acquired via the ESPP earlier in 2025 and that RSUs vest annually provides context on compensation-related flows rather than market-driven trading. From a financial modeling perspective, these moves do not affect revenue, earnings, or outstanding share counts at scale.

Corporate Governance Expert

TL;DR: Routine executive equity activity tied to compensation and personal transactions; not a governance red flag.

The filing documents standard disclosure: RSU vesting, ESPP purchases, and small open-market or plan-related transactions. The presence of an attorney-in-fact signature is common for Form 4 filings and the explanatory footnotes clarify the nature of the holdings and pricing. There are no indications of unusual timing, large-scale disposals, or deviations from company equity-plan schedules based on the information provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Martin Alexander

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2025		M		18	A	$0	1,438.659(1)	D
Common Stock	09/01/2025		F		5	D	$647.09(2)	1,433.659	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(3)	09/01/2025		M			18	(3)	(3)	Common Stock	18	(4)	0	D

Explanation of Responses:

1. Includes a total of 28.709 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.

2. Closing price of Issuer common stock on the Nasdaq Global Select Market on August 29, 2025.

3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning September 1, 2022.

4. Not applicable.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Martin A. Smith	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Martin A. Smith report for IDEXX (IDXX)?

The Form 4 reports an acquisition of 18 shares and a disposition of 5 shares of IDEXX common stock on 09/01/2025.

How many IDEXX shares does Martin A. Smith beneficially own after the reported transactions?

The filing shows beneficial ownership figures of 1,438.659 and 1,433.659 shares following the reported transactions.

Were any restricted stock units (RSUs) disclosed in the Form 4 for IDXX?

Yes. The filing reports 18 RSUs, each representing a contingent right to one share, with the grant vesting in four annual installments beginning September 1, 2022.

What price is shown for the disposed IDEXX shares?

The Form 4 lists a price of $647.09, identified as the Nasdaq closing price on August 29, 2025.

Did the filing disclose shares bought through an ESPP?

Yes. The filing notes 28.709 shares purchased under the issuer’s Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.